Results 161 to 170 of about 109,370 (265)

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Targeted Antiplatelet Therapy

open access: yesPlatelets, 1994
R S, More   +2 more
openaire   +2 more sources

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su   +7 more
wiley   +1 more source

Clopidogrel vs. Aspirin in Double Antithrombotic Therapy for Patients on Oral Anticoagulation Undergoing Coronary Stenting. [PDF]

open access: yesJ Cardiovasc Dev Dis
Pompei G   +7 more
europepmc   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo   +3 more
wiley   +1 more source

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder   +13 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Equine vegetative endocarditis and vertebral osteomyelitis due to refractory Erysipelothrix rhusiopathiae infection

open access: yesEquine Veterinary Education, EarlyView.
Summary Erysipelothrix rhusiopathiae was the causative agent of vegetative endocarditis and vertebral osteomyelitis in a 24‐year‐old Irish draught gelding that presented with prolonged history of intermittent pyrexia and tachycardia. Clinical investigations revealed persistently reduced neck mobility, tachydysrhythmia and episodic pyrexia up to 41°C ...
E. Kolovou   +11 more
wiley   +1 more source

ALOX15 mediates thrombin‐induced myristoylation, trafficking, and interaction of protease‐activated receptors, leading to platelet activation and hemostasis

open access: yesThe FEBS Journal, EarlyView.
The role of PARs in platelet function is fairly known; however, the underlying mechanisms are not fully understood. We report that thrombin myristoylates PAR4 in mouse platelets and PAR1 and PAR4 in human platelets, facilitating their membrane transport and interaction, leading to PAR3/4 heterodimers in mice and PAR1/4 heterodimers in humans.
Suresh Govatati   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy